Previous 10 | Next 10 |
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference PR Newswire SAN FRANCISCO , Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44 th Annual Health Care C...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its fi...
2024-01-22 08:31:49 ET More on DiaMedica Therapeutics Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information for DiaMedica Therapeutics For further details see: DiaMedica The...
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire SAN FRANCISCO , Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42 nd Annual J.P. Morgan H...
2023-12-29 15:30:56 ET More on Inspire Medical Systems Inspire Medical Systems: Time To Wake Up Inspire Medical Systems, Inc. (INSP) Q3 2023 Earnings Call Transcript Inspire Medical Systems, Inc. 2023 Q3 - Results - Earnings Call Presentation Inspire Medical ...
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting PR Newswire – NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-...
2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...
2023-11-07 21:11:10 ET Nektar Therapeutics (NKTR) Q3 2023 Earnings Conference Call November 07, 2023, 05:00 PM ET Company Participants Vivian Wu - Director, IR and Corporate Affairs Howard Robin - President and CEO Jonathan Zalevsky - Chief, Research and Developm...
News, Short Squeeze, Breakout and More Instantly...
Nektar Management to Present at Upcoming Investor Conferences PR Newswire SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare C...
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and ...
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results fo...